BR112016010253A2 - sais de 1-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)- 4-(trifluorometil)-2,3-di-hidro-1h-inden-1-il]-1,2,3,4-tetra-hidropirimidin-5-ácido carboxílico - Google Patents
sais de 1-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)- 4-(trifluorometil)-2,3-di-hidro-1h-inden-1-il]-1,2,3,4-tetra-hidropirimidin-5-ácido carboxílicoInfo
- Publication number
- BR112016010253A2 BR112016010253A2 BR112016010253A BR112016010253A BR112016010253A2 BR 112016010253 A2 BR112016010253 A2 BR 112016010253A2 BR 112016010253 A BR112016010253 A BR 112016010253A BR 112016010253 A BR112016010253 A BR 112016010253A BR 112016010253 A2 BR112016010253 A2 BR 112016010253A2
- Authority
- BR
- Brazil
- Prior art keywords
- dihydro
- salts
- benzoxazol
- inden
- dioxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
sais de 1-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)- 4-(trifluorometil)-2,3-di-hidro-1h-inden-1-il]-1,2,3,4-tetra-hidropirimidin-5-ácido carboxílico. a invenção está relacionada a novos sais de 1-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-trifluorometil)-2,3-di-hidro-1h-inden-1-il]-1,2,3,4-tetra-hidropirimidina-5-ácido carboxílico da fórmula (i), em particular, sais de aminoácidos, como sal de lisina e sais de metal alcalino, como sal de sódio e sal de potássio, a um método para produção do mesmo, a uma medicação contendo o mesmo e a seu uso no tratamento de doenças.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192177 | 2013-11-08 | ||
| PCT/EP2014/073801 WO2015067652A1 (de) | 2013-11-08 | 2014-11-05 | Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016010253A2 true BR112016010253A2 (pt) | 2017-08-08 |
| BR112016010253A8 BR112016010253A8 (pt) | 2021-06-22 |
Family
ID=49552231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016010253A BR112016010253A8 (pt) | 2013-11-08 | 2014-11-05 | sais de 1-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)- 4-(trifluorometil)-2,3-di-hidro-1h-inden-1-il]-1,2,3,4-tetra-hidropirimidin-5-ácido carboxílico |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9926305B2 (pt) |
| EP (1) | EP3066097B1 (pt) |
| JP (1) | JP6446051B2 (pt) |
| KR (1) | KR102351418B1 (pt) |
| CN (1) | CN105658647B (pt) |
| AP (1) | AP2016009181A0 (pt) |
| AU (1) | AU2014345599B2 (pt) |
| BR (1) | BR112016010253A8 (pt) |
| CA (1) | CA2929780C (pt) |
| CL (1) | CL2016001096A1 (pt) |
| CY (1) | CY1119520T1 (pt) |
| DK (1) | DK3066097T3 (pt) |
| EA (1) | EA033132B1 (pt) |
| ES (1) | ES2645480T3 (pt) |
| HK (1) | HK1222171A1 (pt) |
| HR (1) | HRP20171603T1 (pt) |
| HU (1) | HUE035021T2 (pt) |
| IL (1) | IL245407B (pt) |
| LT (1) | LT3066097T (pt) |
| MA (1) | MA39020A1 (pt) |
| ME (1) | ME02907B (pt) |
| MX (1) | MX366848B (pt) |
| MY (1) | MY190108A (pt) |
| NO (1) | NO3066097T3 (pt) |
| PH (1) | PH12016500853A1 (pt) |
| PL (1) | PL3066097T3 (pt) |
| PT (1) | PT3066097T (pt) |
| RS (1) | RS56509B1 (pt) |
| SA (1) | SA516371082B1 (pt) |
| SI (1) | SI3066097T1 (pt) |
| TN (1) | TN2016000170A1 (pt) |
| UA (1) | UA117686C2 (pt) |
| WO (1) | WO2015067652A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3338780A1 (de) | 2016-12-20 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind |
| WO2018197333A1 (en) * | 2017-04-27 | 2018-11-01 | Bayer Aktiengesellschaft | Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad) |
| CN114671856B (zh) * | 2020-12-25 | 2023-10-20 | 广东东阳光药业股份有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| TW202404601A (zh) * | 2022-04-05 | 2024-02-01 | 加拿大商索科普拉健康與人類科學兩合公司 | 用於選擇性消退血栓性或血栓栓塞性疾病中血栓的凝乳酶抑制劑 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4175887B2 (ja) * | 2000-10-19 | 2008-11-05 | 日本化薬株式会社 | 新規血管狭窄治療剤または予防剤 |
| AT511788A1 (de) | 2011-07-29 | 2013-02-15 | Georg Dr Gaul | Vorrichtung zur vorgebbaren anordnung eines stents |
| AU2013230671B2 (en) * | 2012-03-05 | 2016-12-15 | Gratuk Technologies Pty Ltd | Dietary supplement |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| US9695131B2 (en) * | 2013-11-08 | 2017-07-04 | Bayer Pharma Aktiengesellschaft | Substituted uracils as chymase inhibitors |
-
2014
- 2014-11-05 MA MA39020A patent/MA39020A1/fr unknown
- 2014-11-05 MY MYPI2016701615A patent/MY190108A/en unknown
- 2014-11-05 CN CN201480057947.4A patent/CN105658647B/zh active Active
- 2014-11-05 UA UAA201606202A patent/UA117686C2/uk unknown
- 2014-11-05 SI SI201430450T patent/SI3066097T1/sl unknown
- 2014-11-05 WO PCT/EP2014/073801 patent/WO2015067652A1/de active Application Filing
- 2014-11-05 HU HUE14793565A patent/HUE035021T2/en unknown
- 2014-11-05 PT PT147935654T patent/PT3066097T/pt unknown
- 2014-11-05 CA CA2929780A patent/CA2929780C/en active Active
- 2014-11-05 EP EP14793565.4A patent/EP3066097B1/de active Active
- 2014-11-05 PL PL14793565T patent/PL3066097T3/pl unknown
- 2014-11-05 NO NO14793565A patent/NO3066097T3/no unknown
- 2014-11-05 DK DK14793565.4T patent/DK3066097T3/da active
- 2014-11-05 KR KR1020167011771A patent/KR102351418B1/ko active IP Right Grant
- 2014-11-05 AU AU2014345599A patent/AU2014345599B2/en active Active
- 2014-11-05 RS RS20171063A patent/RS56509B1/sr unknown
- 2014-11-05 LT LTEP14793565.4T patent/LT3066097T/lt unknown
- 2014-11-05 TN TN2016000170A patent/TN2016000170A1/en unknown
- 2014-11-05 EA EA201600381A patent/EA033132B1/ru not_active IP Right Cessation
- 2014-11-05 ES ES14793565.4T patent/ES2645480T3/es active Active
- 2014-11-05 US US15/035,165 patent/US9926305B2/en active Active
- 2014-11-05 BR BR112016010253A patent/BR112016010253A8/pt not_active Application Discontinuation
- 2014-11-05 ME MEP-2017-249A patent/ME02907B/me unknown
- 2014-11-05 MX MX2016005971A patent/MX366848B/es active IP Right Grant
- 2014-11-05 AP AP2016009181A patent/AP2016009181A0/en unknown
- 2014-11-05 JP JP2016551038A patent/JP6446051B2/ja active Active
-
2016
- 2016-05-01 IL IL24540716A patent/IL245407B/en active IP Right Grant
- 2016-05-06 CL CL2016001096A patent/CL2016001096A1/es unknown
- 2016-05-06 PH PH12016500853A patent/PH12016500853A1/en unknown
- 2016-05-08 SA SA516371082A patent/SA516371082B1/ar unknown
- 2016-08-30 HK HK16110283.7A patent/HK1222171A1/zh unknown
-
2017
- 2017-10-19 HR HRP20171603TT patent/HRP20171603T1/hr unknown
- 2017-10-25 CY CY20171101110T patent/CY1119520T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| CY1122648T1 (el) | Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη | |
| CL2016001150A1 (es) | Formas sólidas de ácido [(5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]aético, composiciones, y usos de las mismas. | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| DOP2017000191A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| CY1117962T1 (el) | Υδροχλωρικο αλας 4-[2-[[5-μεθυλο-1-(2- ναφθαλενυλο)-1η- πυραζολ-3-υλ]οξυ]αιθυλο] μορφολινης | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| BR112014024833A8 (pt) | Produto farmacêutico veterinário mastigável macio, processo para a fabricação de um produto, uso de ácido pamóico ou um sal farmaceuticamente aceitável do mesmo, uso de um produto farmacêutico veterinário mastigável macio, e, composição farmacêutica veterinária mastigável macia. | |
| DOP2016000253A (es) | Nuevos compuestos | |
| CY1123456T1 (el) | Μεθοδος παρασκευης οπτικως καθαρων και προαιρετικως υποκατεστημενων παραγωγων 2-(1-υδροξυ-αλκυλ)-χρωμεν-4-ονης και χρηση αυτων στην παρασκευη φαρμακευτικων ουσιων | |
| EA201492040A1 (ru) | Бициклически замещённые урацилы и их применение | |
| CR20140053A (es) | Formulaciones de ácido desoxicólico y sales del mismo | |
| BR112016028749A2 (pt) | composto, forma cristalina, composição farmacêutica, e, método para o tratamento de uma doença. | |
| EA201591618A1 (ru) | Замещенные имидазопиридазины | |
| CY1119520T1 (el) | Αλατα 1-(3-μεθυλ-2-οξο-2,3-διυδρο-1,3-βενζοξαζολ-6-υλ)-2,4-διοξο-3-[(1r)-4-(τριφθορομεθυλ)-2,3-διυδρο-1η-ινδενο-1-υλ]-1,2,3,4-τετραϋδροπυριμιδιν-5-καρβοξυλικου οξεος | |
| CY1123877T1 (el) | Μορφες στερεας καταστασης αλατων νιλοτινιμπης | |
| CR20140325A (es) | Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2- | |
| EA201490045A1 (ru) | Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении | |
| GT201300089A (es) | Nuevas formas cristalinas de la sal sodica del acido (4-(4-(5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il)-fenil)-ciclohexil)-acetico | |
| EA201790223A1 (ru) | Водный препарат, содержащий парацетамол и ибупрофен | |
| BR112014008783A2 (pt) | compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório | |
| DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
| BR112013011015A2 (pt) | formas sólidas de ácido (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetóxi)pirimidin-4-il)fenil)propanoico | |
| EA201591704A1 (ru) | Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии | |
| BR112014017889A8 (pt) | Glóbulos, uso dos glóbulos, produtos para ração e pré-mistura para produtos para ração |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |